Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Circadian Rhythm on Anti-PD-1/PD-L1 Immunotherapy
NCT07224971Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) and solid tumor (2 arms). Primary endpoint: Real-world progression-free survival up to 4.5 years. Started Dec 2025; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT07224971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224971.